Biomimetic Nanoplatelets to Target Delivery Hirudin for Site-Specific Photothermal/Photodynamic Thrombolysis and Preventing Venous Thrombus Formation,Small

当前位置： X-MOL 学术 › Small › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Biomimetic Nanoplatelets to Target Delivery Hirudin for Site-Specific Photothermal/Photodynamic Thrombolysis and Preventing Venous Thrombus Formation
Small ( IF 13.0 ) Pub Date : 2022-11-07 , DOI: 10.1002/smll.202203184
Shuting Li ₁ , Kai Zhang ₁ , Zhaoyu Ma ₁ , Weiyun Zhang ₁ , Zhiyong Song ₂ , Wenjing Wang ₂ , Heyou Han _{1,

2}

Affiliation

Due to the high recurrence rate and mortality of venous thrombosis, there is an urgent need for research on antithrombotic strategies. Because of the short half-life, poor targeting capabilities, bleeding complications, and neurotoxic effects of conventional pharmacological thrombolysis methods, it is essential to develop an alternative strategy to noninvasive thrombolysis and decrease the recurrence rate of venous thrombosis. A platelet-mimetic porphyrin-based covalent organic framework-engineered melanin nanoplatform, to target delivery of hirudin to the vein thrombus site for noninvasive thrombolysis and effective anticoagulation, is first proposed. Owing to the thrombus-hosting properties of platelet membranes, the nanoplatform can target the thrombus site and then activate hyperthermia and reactive oxygen species for thrombolysis under near-infrared light irradiation. The photothermal therapy/photodynamic therapy combo can substantially improve the effectiveness (85.7%) of thrombolysis and prevent secondary embolism of larger fragments. Afterward, the highly loaded (97%) and slow-release hirudin (14 days) are effective in preventing the recurrence of blood clots without the danger of thrombocytopenia. The described biomimetic nanostructures offer a promising option for improving the efficacy of thrombolytic therapy and reducing the risk of bleeding complications in thrombus associated diseases.

中文翻译：

仿生纳米血小板靶向递送水蛭素用于位点特异性光热/光动力血栓溶解和预防静脉血栓形成

由于静脉血栓形成的复发率和死亡率较高，因此迫切需要研究抗栓策略。由于传统药物溶栓方法的半衰期短、靶向能力差、出血并发症和神经毒性作用，因此有必要开发一种替代无创溶栓的策略，并降低静脉血栓形成的复发率。首次提出了一种基于仿血小板卟啉的共价有机骨架工程黑色素纳米平台，用于将水蛭素靶向递送至静脉血栓部位，以进行无创溶栓和有效抗凝。由于血小板膜的血栓宿主特性，纳米平台可以靶向血栓部位，然后在近红外光照射下激活热疗和活性氧来溶栓。光热疗法/光动力疗法组合可以显着提高溶栓的有效性（85.7%）并防止较大碎片的二次栓塞。之后，高负荷（97%）和缓释水蛭素（14 天）可有效预防血栓复发，而没有血小板减少症的危险。所描述的仿生纳米结构为提高溶栓治疗的疗效和降低血栓相关疾病出血并发症的风险提供了一个有前途的选择。7%）的溶栓作用，防止较大碎片的继发性栓塞。之后，高负荷（97%）和缓释水蛭素（14 天）可有效预防血栓复发，而没有血小板减少症的危险。所描述的仿生纳米结构为提高溶栓治疗的疗效和降低血栓相关疾病出血并发症的风险提供了一个有前途的选择。7%）的溶栓作用，防止较大碎片的继发性栓塞。之后，高负荷（97%）和缓释水蛭素（14 天）可有效预防血栓复发，而没有血小板减少症的危险。所描述的仿生纳米结构为提高溶栓治疗的疗效和降低血栓相关疾病出血并发症的风险提供了一个有前途的选择。

更新日期：2022-11-07

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南